# Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

> **NCT00852189** · PHASE1 · COMPLETED · sponsor: **Endocyte** · enrollment: 65 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** EC0489, Injection
- **DRUG:** EC20
- **DRUG:** EC0489, Injection

## Key facts

- **NCT ID:** NCT00852189
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-12
- **Final completion:** 2012-04
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2012-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00852189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00852189, "Study of EC0489 for the Treatment of Refractory or Metastatic Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00852189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*